Sidley Austin adds ex-FDA counsel Troy
Executive Summary
Former FDA Chief Counsel Dan Troy and Special Assistant Coleen Klaismeier join Sidley Austin Brown & Wood's life sciences practice. Troy will also serve in the appellate litigation division. Troy and Klaismeier left FDA in December; Troy was the first political appointee at FDA in the Bush Administration (1"The Pink Sheet" Nov. 22, 2004, p. 15)...
You may also be interested in...
FDA Chief Counsel Troy Resigns; Agency Says It Will Still Support Preemption
FDA will continue to protect its regulatory authority by supporting federal preeminence in state product liability suits following the departure of Chief Counsel Dan Troy, Acting Commissioner Lester Crawford said
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.